uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial
McGill Univ, Hlth Ctr, 1650 Cedar Ave,Room E5-200, Montreal, PQ H3G 1A4, Canada.;Hop Sacre Coeur, Montreal, PQ, Canada..
Swansea Univ, Cardiol Dept, Morriston Hosp, Swansea SA6 6NL, W Glam, Wales.;Luigi Sacco Hosp, Cardiol Dept, Milan, Italy..
Univ Ottawa Heart Inst, Ottawa, ON, Canada..
McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada..
Show others and affiliations
2017 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 19, no 10, p. 1630-1636Article in journal (Refereed) Published
Abstract [en]

Aims: Cardiac implantable electronic device (CIED) surgery is commonly performed in patients with atrial fibrillation (AF). The current analysis was undertaken to compare peri-operative anticoagulation management, bleeding, and thrombotic events in AF patients treated with dabigatran vs. warfarin.

Methods and results: This study included 611 patients treated with dabigatran vs. warfarin who underwent CIED surgery during the RE-LY trial. Among 201 warfarin-treated patients, warfarin was interrupted a median of 144 (inter-quartile range, IQR: 120-216) h, and 37 (18.4%) patients underwent heparin bridging. In dabigatran-treated patients (216 on 110 mg bid and 194 on 150 mg bid), the duration of dabigatran interruption was a median of 96 (IQR: 61-158) h. Pocket hematomas occurred in 9 (2.20%) patients on dabigatran and 8 (3.98%) patients on warfarin (P = 0.218). The occurrence of pocket hematomas was lower with dabigatran compared with warfarin with heparin bridging (RD: -8.62%, 95% CI: -24.15 to - 0.51%, P = 0.034) but not when compared with warfarin with no bridging (P = 0.880). Ischemic stroke occurred in 2 (0.3%) patients; one in the warfarin group (without bridging) and one in the dabigatran 150 mg bid group (P = 0.735).

Conclusion: In patients treated with dabigatran undergoing CIED surgery, interruption of dabigatran is associated with similar or lower incidence of pocket hematoma, when compared with warfarin interruption without or with heparin bridging, respectively. Whether uninterrupted dabigatran can reduce pocket hematoma or ischemic stroke remains to be evaluated.

Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2017. Vol. 19, no 10, p. 1630-1636
Keywords [en]
Dabigatran, Warfarin, Hematoma, Anticoagulation, Device implantation
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:uu:diva-338524DOI: 10.1093/europace/euw409ISI: 000412840300003PubMedID: 28339794OAI: oai:DiVA.org:uu-338524DiVA, id: diva2:1172505
Available from: 2018-01-10 Created: 2018-01-10 Last updated: 2018-01-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Oldgren, Jonas

Search in DiVA

By author/editor
Oldgren, Jonas
By organisation
UCR-Uppsala Clinical Research CenterCardiology
In the same journal
Europace
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf